



February 06, 2012

BSE Limited  
Corporate Service Department  
1st Floor, New Trading Ring  
Rotunda Building, P.J.Tower  
Dalal Street, Fort  
**Mumbai - 400 001**

The National Stock Exchange of India Ltd.  
Exchange Plaza  
Bandra Kurla Complex  
Bandra (E)  
**Mumbai – 400 051**

Dear Sir,

In terms of Clause 41 of the Listing Agreement, the Unaudited Financial Results of the Company for the quarter ended December 31, 2011 were approved by the Board of Directors in their meeting held on February 06, 2012.

A copy of the Unaudited Financial Results for the quarter ended December 31, 2011 duly signed by the Chairman & Managing Director of the Company is enclosed alongwith Limited Review Report thereon.

We are also sending a copy of the press release and presentation.

Thanking you,

Yours faithfully,  
for JUBILANT LIFE SCIENCES LTD.

  
**LALIT JAIN**  
Company Secretary

Encl: as above

A Jubilant Bhartia Company

OUR VALUES



**Jubilant Life Sciences Limited**  
(Formerly Jubilant Organosys Ltd)  
1-A, Sector 16-A,  
Noida-201 301, UP, India  
Tel: +91 120 2516601-11  
Fax: +91 120 2516629  
[www.jubl.com](http://www.jubl.com)

Regd Office:  
Bhartiagram, Gajraula  
Distt. Jyotiba Phoolay Nagar- 244 223  
UP, India

**Jubilant Life Sciences Ltd**  
(Formerly Jubilant Organosys Ltd.)

Regd. Off: Bhartiagram, Gajraula, Distt. Jyotiba Phoolay Nagar-244 223 (U.P.)  
Unaudited Financial Results for the Quarter and Nine Months ended 31st December, 2011

(₹ in Lacs)

STAND ALONE RESULTS						Particulars	CONSOLIDATED RESULTS					
Quarter Ended			Nine Months Ended		Year Ended		Quarter Ended			Nine Months Ended		Year Ended
December 31	September 30	December 31	December 31		March 31		December 31	September 30	December 31	December 31		March 31
(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)		(Audited)		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)		(Audited)
2011	2011	2010	2011	2010	2011	2011	2011	2010	2011	2010	2011	
67451	62837	57957	191990	164050	220089	Net sales/Income from operations	108717	104808	86647	307954	254306	343340
333	266	162	772	235	541	Other Operating Income	132	200	250	751	480	883
67784	63103	58119	192762	164285	220630	Total income	108849	105008	86897	308705	254786	344223
60008	54963	49759	167178	136194	186069	Total expenditure	93399	86282	78610	260885	227294	306812
(5188)	(2467)	1550	(9872)	(401)	(3131)	a) (Increase)/Decrease in stock in trade and work in progress	(10461)	(4522)	1073	(19184)	(832)	(3880)
5902	6065	5822	17471	16097	21637	b) Purchase of traded goods	8345	6554	7289	21484	17603	24007
33728	29893	21832	92076	65223	90143	c) Raw & process materials consumed	41140	36657	26805	111375	82368	112943
3117	2232	2960	8209	7210	9424	d) Stores, spares, chemicals, catalyst & packing material consumed	6314	5113	5679	17299	16112	21188
7364	5349	5141	18257	14745	20665	e) Power & fuel	7749	5822	5523	19572	16044	22404
1929	1801	960	4993	3367	4895	f) Other manufacturing expenses	2568	2539	1473	6910	4762	6965
5606	5090	4577	15374	12504	17317	g) Staff cost	22817	20603	17765	62396	53543	71842
3228	2921	2526	8917	7394	9991	h) Depreciation	5389	5080	4928	15446	14696	18010
4322	4079	4391	11753	10055	15128	i) Other Expenditure (Selling, general & admin. Expenses-Including Exchange Loss/Gain)	9538	8436	8075	25587	22998	33333
7776	8140	8360	25584	28091	34561	Operating profit before Other Income & Interest	15450	18726	8287	47820	27492	37411
189	229	97	653	213	514	Other Income	351	340	168	1058	825	1296
7965	8369	8457	26237	28304	35075	Profit before Interest & Exceptional Items	15801	19066	8455	48878	28317	38707
4218	3599	1516	10818	2922	4625	Interest (Net)	5662	4969	2856	14969	7279	10506
3747	4770	6941	15419	25382	30450	Profit after Interest but before Exceptional Items	10139	14097	5599	33909	21038	28201
15322	4160	(650)	19750	(73)	455	Exceptional items	15549	4260	230	20227	2601	4142
(11575)	610	7591	(4331)	25455	29995	Profit from Ordinary Activities before Tax	(5410)	9837	5369	13682	18437	24059
2127	110	449	3482	2660	2032	Tax Expenses (Net)	888	930	1037	3334	1875	1336
(13702)	500	7142	(7813)	22795	27963	Net profit from Ordinary Activities after Tax	(6298)	8907	4332	10348	16562	22723
-	-	-	-	-	-	Extraordinary Items (net of tax expenses)	-	-	-	-	-	-
-	-	-	-	-	-	Minority Interest	1541	971	(79)	2539	(238)	(249)
(13702)	500	7142	(7813)	22795	27963	Net profit after Minority Interest	(7839)	7936	4411	7809	16800	22972
1593	1593	1593	1593	1593	1593	Paid-up share capital (Face value per share ₹ 1)	1593	1593	1593	1593	1593	1593
					212466	Reserves (excluding revaluation reserve)						215634
						Earnings per share before and after extraordinary items (Not annualized)						
(8.60)	0.31	4.48	(4.91)	14.31	17.56	Basic (₹)	(4.92)	4.98	2.77	4.90	10.55	14.42
(8.60)	0.31	4.05	(4.91)	12.94	15.87	Diluted (₹)	(4.92)	4.98	2.50	4.90	9.54	13.04
81166083	81344677	84129115	81166083	84129115	84129115	Public shareholding	81166083	81344677	84129115	81166083	84129115	84129115
50.96	51.07	52.82	50.96	52.82	52.82	- Number of shares (₹ 1 each)	50.96	51.07	52.82	50.96	52.82	52.82
						- Percentage of shareholding						
						Promoters and promoter group Shareholding						
						a) Pledged/Encumbered						
4257000	6552333	7228300	4257000	7228300	7531333	- Number of shares	4257000	6552333	7228300	4257000	7228300	7531333
5.45	8.41	9.62	5.45	9.62	10.02	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	5.45	8.41	9.62	5.45	9.62	10.02
2.67	4.11	4.54	2.67	4.54	4.73	- Percentage of shares (as a % of the total share capital of the company)	2.67	4.11	4.54	2.67	4.54	4.73
						b) Non-Encumbered						
73858056	71384129	67923724	73858056	67923724	67620691	- Number of shares	73858056	71384129	67923724	73858056	67923724	67620691
94.55	91.59	90.38	94.55	90.38	89.98	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	94.55	91.59	90.38	94.55	90.38	89.98
46.37	44.82	42.64	46.37	42.64	42.45	- Percentage of shares (as a % of the total share capital of the company)	46.37	44.82	42.64	46.37	42.64	42.45



**Notes:**

1. The Company's operates under one reportable segment viz. Pharmaceuticals and Life Sciences Products and Services (PLSPS).
2. The Company has opted for accounting of exchange difference arising on reporting of long term monetary items under Clause 46 A of AS 11 on "The Effects of Changes in Foreign Exchange Rates" as per notification No GSR 914(E) issued by the Ministry of Corporate Affairs Government of India on 29th December, 2011. Accordingly exchange differences amounting to ₹ 4108 Lacs has been amortized during the nine months period ending 31st December, 2011 and balance ₹ 10949 Lacs has been carried forward under Foreign Currency Monetary Items Translation Difference Account (FCMITDA) to be amortized over the balance life of the respective loan and ₹ 641 Lacs has been taken to Capital work in Progress.
3. The company has opted for hedge accounting in respect of certain transactions including forward contracts under Accounting Standard 30 issued by the Institute of Chartered Accountants of India during the period and the debit balance in hedge reserve as at 31st December 2011 is ₹ 6582 Lacs (Consolidated ₹ 7259 Lacs) .
4. During the quarter the company acquired 100% stake in an entity which holds 4.20% shares in its subsidiary Jubilant First Trust Healthcare Limited (JFTH) and as a result JFTH has become wholly owned Subsidiary of the Company .
5. During the quarter the Company has commenced commercial production of Nutrition Ingredients and Fine Chemicals at its SEZ in Bharuch, Gujarat .
6. Exceptional items include :
  - i) Amortization of Foreign Currency Monetary Item Translation Difference Account-loss/(gain) ₹ 1257 Lacs (Consolidated ₹ 1257 Lacs) for Q3-FY 2012 and ₹ 4108 Lacs (Consolidated ₹ 4108 Lacs) for 9M-FY 2012.
  - ii) Mark to Market in respect of Currency & Interest rate swap contracts and Forward Covers outstanding at the period end resulting in loss/(gain) amounting to ₹ 14065 Lacs (Consolidated ₹ 14292 Lacs) for Q3-FY 2012 and ₹ 15642 Lacs (Consolidated ₹ 16119 Lacs) for 9M-FY 2012.
7. Tax Expenses are net after considering the Deferred Tax charge/credit and MAT Credit Entitlement .
8. Information on investors complaints for the quarter (Nos.): Opening Balance - Nil, New -32, Disposals -32, Closing Balance - Nil.
9. Previous year / periods figures have been regrouped/reclassified wherever necessary.
10. The above un-audited results were , subjected to limited review by the auditors of the Company, reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 6th February, 2012.

Place : Noida

Dated : 6th February, 2012



For Jubilant Life Sciences Ltd.

Shyam S Bhartia  
Chairman & Managing Director

**K.N. GUTGUTIA & CO.**

**CHARTERED ACCOUNTANTS**

**KOLKATA : NEW DELHI**

**11 K GOPALA TOWER, 25, RAJENDRA PLACE,  
NEW DELHI-110008**

**Office : 25713944, 25788644  
Telefax : 25818644**

**Email : kng1938@vsnl.net  
Website : www.cakng.com**

**LIMITED REVIEW REPORT FOR THE QUARTER & NINE MONTHS ENDED  
31<sup>st</sup> DECEMBER, 2011**

**TO THE BOARD OF DIRECTORS OF  
JUBILANT LIFE SCIENCES LTD.**

We have reviewed the accompanying Statement of Unaudited Financial Results of **Jubilant Life Sciences Limited** for the quarter & Nine months ended 31<sup>st</sup> December, 2011, *except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us.* This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditors of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquire of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention, that causes us to believe that the accompanying Statement of Unaudited Financial Results, prepared in accordance with applicable Accounting Standards and other recognized accounting Practices and policies and measurement principle laid down in Accounting Standard 25 "Interim Financial Reporting" (notified pursuant of the Companies (Accounting Standards) Rules 2006, (as amended), has not disclosed the information required to be disclosed in terms of clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

**FOR K.N.GUTGUTIA & COMPANY  
CHARTERED ACCOUNTANTS  
ICAI'S FRN 304153E**



**(B.R.GOYAL)**

**PARTNER**

**M.NO. 12172**

**Dated: 06.02.2012**

